The Lancet Gastroenterology & Hepatology in conversation with

Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease


Listen Later

Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.

Read the full articles:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00264-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00233-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!

Follow us today at...

https://bsky.app/profile/lancetgastrohep.bsky.social

https://www.linkedin.com/company/langastro/

https://instagram.com/thelancetgroup

https://facebook.com/thelancetmedicaljournal

https://youtube.com/thelancettv

...more
View all episodesView all episodes
Download on the App Store

The Lancet Gastroenterology & Hepatology in conversation withBy The Lancet Group


More shows like The Lancet Gastroenterology & Hepatology in conversation with

View all
American Journal of Gastroenterology Author Podcasts by American College of Gastroenterology

American Journal of Gastroenterology Author Podcasts

70 Listeners

The Lancet Voice by The Lancet Group

The Lancet Voice

22 Listeners

The Lancet Child & Adolescent Health in conversation with by The Lancet Group

The Lancet Child & Adolescent Health in conversation with

0 Listeners

The Lancet Digital Health in conversation with by The Lancet Group

The Lancet Digital Health in conversation with

0 Listeners

The Lancet Global Health in conversation with by The Lancet Group

The Lancet Global Health in conversation with

2 Listeners

The Lancet Oncology in conversation with by The Lancet Group

The Lancet Oncology in conversation with

1 Listeners

The Lancet Psychiatry in conversation with by The Lancet Group

The Lancet Psychiatry in conversation with

0 Listeners

The Lancet Respiratory Medicine in conversation with by The Lancet Group

The Lancet Respiratory Medicine in conversation with

1 Listeners

The Lancet in conversation with by The Lancet Group

The Lancet in conversation with

0 Listeners

The Lancet Haematology in conversation with by The Lancet Group

The Lancet Haematology in conversation with

0 Listeners

The Lancet Diabetes & Endocrinology in conversation with by The Lancet Group

The Lancet Diabetes & Endocrinology in conversation with

1 Listeners

The Lancet Infectious Diseases in conversation with by The Lancet Group

The Lancet Infectious Diseases in conversation with

0 Listeners

The Lancet Public Health in conversation with by The Lancet Group

The Lancet Public Health in conversation with

1 Listeners

The Lancet Microbe in conversation with by The Lancet Group

The Lancet Microbe in conversation with

0 Listeners

eBioMedicine in conversation with by The Lancet Group

eBioMedicine in conversation with

0 Listeners

In conversation with... by The Lancet Neurology

In conversation with...

0 Listeners

The Lancet Rheumatology in conversation with by The Lancet Group

The Lancet Rheumatology in conversation with

0 Listeners

The Lancet Regional Health in conversation with by The Lancet Group

The Lancet Regional Health in conversation with

0 Listeners

The Lancet Primary Care in conversation with by The Lancet Group

The Lancet Primary Care in conversation with

0 Listeners

The Lancet Regional Health Americas in conversation with by The Lancet Group

The Lancet Regional Health Americas in conversation with

0 Listeners